• 1
    Huang, Z. (2005) A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 4, 283293.
  • 2
    Celli, J. P., B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue and T. Hasan (2010) Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem. Rev. 110, 27952838
  • 3
    Hasan, T., B. Ortel, N. Solban and B. Pogue (2006) Photodynamic therapy of cancer. In Cancer Medicine, (Edited by D. W. Kufe, R. C. J. Bast, W. N. Hait, W. K. Hong, R. E. Pollock, R. R. Weichselbaum, J. F. Holland and E. I. Frei), pp. 537548. B.C. Decker, Inc., Hamilton, Ontario.
  • 4
    Smits, T. and A. C. Moor (2009) New aspects in photodynamic therapy of actinic keratoses. J. Photochem. Photobiol., B 96, 159169.
  • 5
    Brown, S., E. Brown and I. Walker (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncology 5, 497508.
  • 6
    Wilson, B. and M. Patterson (2008) The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 53, 61.
  • 7
    Wilson, B. C. (2002) Photodynamic therapy for cancer: Principles. Can J Gastroenterol 16, 393396.
  • 8
    Busch, T. M., S. M. Hahn, E. P. Wileyto, C. J. Koch, D. L. Fraker, P. Zhang, M. Putt, K. Gleason, D. B. Shin, M. J. Emanuele, K. Jenkins, E. Glatstein and S. M. Evans (2004) Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin. Cancer Res. 10, 46304638.
  • 9
    Hahn, S. M., D. L. Fraker, R. Mick, J. Metz, T. M. Busch, D. Smith, T. Zhu, C. Rodriguez, A. Dimofte and F. Spitz (2006) A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and Sarcomatosis. Clin. Cancer Res. 12, 2517.
  • 10
    DeLaney, T. F., W. F. Sindelar, Z. Tochner, P. D. Smith, W. S. Friauf, G. Thomas, L. Dachowski, J. W. Cole, S. M. Steinberg and E. Glatstein (1993) Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int. J. Radiat. Oncol. Biol. Phys. 25, 445457.
  • 11
    Sindelar, W. F., T. F. DeLaney, Z. Tochner, G. F. Thomas, L. J. Dachoswki, P. D. Smith, W. S. Friauf, J. W. Cole and E. Glatstein (1991) Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Phase I Study. Arch Surg 126, 318324.
  • 12
    Hendren, S. K., S. M. Hahn, F. R. Spitz, T. W. Bauer, S. C. Rubin, T. Zhu, E. Glatstein and D. L. Fraker (2001) Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann. Surg. Oncol. 8, 6571.
  • 13
    Wilson, J. J., H. Jones, M. Burock, D. Smith, D. L. Fraker, J. Metz, E. Glatstein and S. M. Hahn (2004) Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int. J. Oncol. 24, 711717.
  • 14
    Wierrani, F., D. Fiedler, W. Grin, M. Henry, E. Dienes, K. Gharehbaghi, B. Krammer and W. Grunberger (1997) Clinical effect of meso-tetrahydroxyphenylchlorine based photodynamic therapy in recurrent carcinoma of the ovary: Preliminary results. Br. J. Obstet. Gynaecol. 104, 376378.
  • 15
    Agostinis, P., K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B. C. Wilson and J. Golab (2011) Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 61, 250281.
  • 16
    Jarvi, M., M. Patterson and B. Wilson (2012) Insights into photodynamic therapy dosimetry: Simultaneous singlet oxygen luminescence and photosensitizer photobleaching measurements. Biophys. J. 102, 661732.
  • 17
    Pogue, B. W. and T. Hasan (1997) A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat. Res. 147, 551559.
  • 18
    Zhou, X., B. W. Pogue, B. Chen, E. Demidenko, R. Joshi, J. Hoopes and T. Hasan (2006) Pretreatment photosensitizer dosimetry reduces variation in tumor response. Int. J. Radiat. Oncol. Biol. Phys. 64, 12111220.
  • 19
    Aveline, B., T. Hasan and R. W. Redmond (1994) Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem. Photobiol. 59, 328335.
  • 20
    Foster, T. H., D. F. Hartley, M. G. Nichols and R. Hilf (1993) Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res. 53, 12491254.
  • 21
    Gibson, S. L., J. J. Havens, T. H. Foster and R. Hilf (1997) Time-dependent intracellular accumulation of delta-aminolevulinic acid, induction of porphyrin synthesis and subsequent phototoxity. Photochem. Photobiol. 65, 416421.
  • 22
    Finlay, J. C., S. Mitra, M. S. Patterson and T. H. Foster (2004) Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms. Phys. Med. Biol. 49, 48374860.
  • 23
    Weston, M. and M. Patterson (2011) Calculation of singlet oxygen dose using explicit and implicit dose metrics during benzoporphyrin derivative monoacid ring A (BPD-MA)-PDT in vitro and correlation with MLL cell survival. Photochem. Photobiol. 87, 11291166.
  • 24
    Henderson, B., T. Busch and J. Snyder (2006) Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 38, 489582.
  • 25
    Dougherty, T. J., C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan and Q. Peng (1998) Photodynamic therapy. J. Natl Cancer Inst. 90, 889905.
  • 26
    Hopper, C. (2000) Photodynamic therapy: A clinical reality in the treatment of cancer. Lancet Oncol 1, 212219.
  • 27
    Moesta, K. T., W. R. Greco, S. O. Nurse-Finlay, J. C. Parsons and T. S. Mang (1995) Lack of reciprocity in drug and light dose dependence of photodynamic therapy of pancreatic adenocarcinoma in vitro. Cancer Res. 55, 30783084.
  • 28
    Lilge, L., K. Molpus, T. Hasan and B. C. Wilson (1998) Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma. Photochem. Photobiol. 68, 281288.
  • 29
    Lee, S., K. Galbally-Kinney, M. Hinds, J. O'Hara, B. Pogue, A. Liang, T. Hasan and S. Davis (2009) A singlet oxygen monitor as an in vivo photodynamic therapy dosimeter. SPIE Proceedings From Photodynamic Therapy: Back to the Future 7380, 738046.
  • 30
    Pogue, B. W., C. Sheng, J. Benevides, D. Forcione, B. Puricelli, N. Nishioka and T. Hasan (2008) Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus. Journal of Biomedical Optics 13, 10.
  • 31
    Samkoe, K. S., A. Chen, I. Rizvi, J. A. O'Hara, P. J. Hoopes, S. P. Pereira, T. Hasan and B. W. Pogue (2010) Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int. J. Radiat. Oncol. Biol. Phys. 76, 251259.
  • 32
    Iinuma, S., K. T. Schomacker, G. Wagnieres, M. Rajadhyaksha, M. Bamberg, T. Momma and T. Hasan (1999) In vivo fluence rate and fractionation effects on tumor response and photobleaching: Photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res. 59, 61646170.
  • 33
    Laubach, H., S. Chang, S. Lee, I. Rizvi, D. Zurakowski, S. Davis, C. Taylor and T. Hasan (2008) In-vivo singlet oxygen dosimetry of clinical 5-aminolevulinic acid photodynamic therapy. Journal of Biomedical Optics 13, 050504.
  • 34
    Ortel, B., N. Chen, J. Brissette, G. P. Dotto, E. Maytin and T. Hasan (1998) Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br. J. Cancer 77, 17441751.
  • 35
    Ortel, B., D. Sharlin, D. O'Donnell, A. K. Sinha, E. V. Maytin and T. Hasan (2002) Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br. J. Cancer 87, 13211327.
  • 36
    Chang, S. K., I. Rizvi, N. Solban and T. Hasan (2008) In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin. Cancer Res. 14, 41464153.
  • 37
    Aveline, B. M., T. Hasan and R. W. Redmond (1995) The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). Journal of Photochemistry and Photobiology. B, Biology 30, 161169.
  • 38
    Dysart, J. S. and M. S. Patterson (2006) Photobleaching kinetics, photoproduct formation, and dose estimation during ALA induced PpIX PDT of MLL cells under well oxygenated and hypoxic conditions. Photochemical & Photobiological Sciences: Official Journal of the European Photochemistry Association and the European Society for Photobiology 5, 7381.
  • 39
    Jarvi, M., M. Niedre, M. Patterson and B. Wilson (2006) Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: Current status, challenges and future prospects. Photochem. Photobiol. 82, 11981210.
  • 40
    Dysart, J. S. and M. S. Patterson (2005) Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro. Phys. Med. Biol. 50, 25972616.
  • 41
    Niedre, M. J., A. J. Secord, M. S. Patterson and B. C. Wilson (2003) In vitro tests of the validity of singlet oxygen luminescence measurements as a dose metric in photodynamic therapy. Cancer Res. 63, 79867994.
  • 42
    Weishaupt, K. R., C. J. Gomer and T. J. Dougherty (1976) Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 36, 23262329.
  • 43
    Georgakoudi, I. and T. H. Foster (1998) Singlet oxygen- versus nonsinglet oxygen-mediated mechanisms of sensitizer photobleaching and their effects on photodynamic dosimetry. Photochem. Photobiol. 67, 612625.
  • 44
    Georgakoudi, I., M. Nichols and T. Foster (1997) The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem. Photobiol. 65, 135144.
  • 45
    Aveline, B. and R. Redmond (1999) Can cellular phototoxicity be accurately predicted on the basis of sensitizer Photophysics? Photochem. Photobiol. 69, 306316.
  • 46
    Potter, W. R., T. S. Mang and T. J. Dougherty (1987) The theory of photodynamic therapy dosimetry: Consequences of photo-destruction of sensitizer. Photochem. Photobiol. 46, 97101.
  • 47
    Fingar, V. H., W. R. Potter and B. W. Henderson (1987) Drug and light dose dependence of photodynamic therapy: A study of tumor cell clonogenicity and histologic changes. Photochem. Photobiol. 45, 643650.
  • 48
    Betz, C. S., W. Rauschning, E. P. Stranadko, M. V. Riabov, V. Albrecht, N. E. Nifantiev and C. Hopper (2008) Optimization of treatment parameters for Foscan®-PDT of basal cell carcinomas. Lasers Surg. Med. 40, 300311.
  • 49
    Mathews, M., E. Angell-Petersen, R. Sanchez, C.-H. Sun, V. Vo, H. Hirschberg and S. Madsen (2009) The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids. Lasers Surg. Med. 41, 578662.
  • 50
    Gibson, S. L., K. R. VanDerMeid, R. S. Murant, R. F. Raubertas and R. Hilf (1990) Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res. 50, 72367241.
  • 51
    Foster, T. H., R. S. Murant, R. G. Bryant, R. S. Knox, S. L. Gibson and R. Hilf (1991) Oxygen consumption and diffusion effects in photodynamic therapy. Radiat. Res. 126, 296303.
  • 52
    Celli, J. P., I. Rizvi, C. L. Evans, A. O. Abu-Yousif and T. Hasan (2010) Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model. Journal of Biomedical Optics 15, 051603051610.
  • 53
    Rizvi, I., J. P. Celli, C. L. Evans, A. O. Abu-Yousif, A. Muzikansky, B. W. Pogue, D. Finkelstein and T. Hasan (2010) Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res. 70, 93199328.
  • 54
    Cho, K. R. and M. Shih Ie (2009) Ovarian cancer. Annu. Rev. Pathol. 4, 287313.
  • 55
    Bast, R. C. Jr, B. Hennessy and G. B. Mills (2009) The biology of ovarian cancer: New opportunities for translation. Nat. Rev. Cancer 9, 415428.
  • 56
    Siegel, R., D. Naishadham and A. Jemal (2012) Cancer statistics, 2012. CA Cancer J. Clin. 62, 1029.
  • 57
    Evans, S. M., K. D. Judy, I. Dunphy, W. T. Jenkins, W. T. Hwang, P. T. Nelson, R. A. Lustig, K. Jenkins, D. P. Magarelli, S. M. Hahn, R. A. Collins, M. S. Grady and C. J. Koch (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 10, 81778184.
  • 58
    Evans, S. M., K. D. Judy, I. Dunphy, W. T. Jenkins, P. T. Nelson, R. Collins, E. P. Wileyto, K. Jenkins, S. M. Hahn, C. W. Stevens, A. R. Judkins, P. Phillips, B. Geoerger and C. J. Koch (2004) Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 64, 18861892.
  • 59
    Bogaards, A., A. Varma, K. Zhang, D. Zach, S. K. Bisland, E. H. Moriyama, L. Lilge, P. J. Muller and B. C. Wilson (2005) Fluorescence image-guided brain tumour resection with adjuvant metronomic photodynamic therapy: Pre-clinical model and technology development. Photochem. Photobiol. Sci. 4, 438442.
  • 60
    Stepp, H., T. Beck, T. Pongratz, T. Meinel, F.-W. Kreth, J. C. Tonn and W. Stummer (2007) ALA and malignant glioma: Fluorescence-guided resection and photodynamic treatment. J. Environ. Pathol. Toxicol. Oncol. 26, 157164.
  • 61
    Beck, T. J., F. W. Kreth, W. Beyer, J. H. Mehrkens, A. Obermeier, H. Stepp, W. Stummer and R. Baumgartner (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg. Med. 39, 386393.
  • 62
    Olzowy, B., C. S. Hundt, S. Stocker, K. Bise, H. J. Reulen and W. Stummer (2002) Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J. Neurosurg. 97, 970976.
  • 63
    Biel, M. A. (1998) Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope 108, 12591268.
  • 64
    de Bree, R. and C. R. Leemans (2010) Recent advances in surgery for head and neck cancer. Curr. Opin. Oncol., 22, 186193.
  • 65
    Rigual, N. R., K. Thankappan, M. Cooper, M. A. Sullivan, T. Dougherty, S. R. Popat, T. R. Loree, M. A. Biel and B. Henderson (2009) Photodynamic therapy for head and neck dysplasia and cancer. Arch. Otolaryngol. Head Neck Surg. 135, 784788.
  • 66
    Zhu, T. C., J. C. Finlay and S. M. Hahn (2005) Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J. Photochem. Photobiol., B 79, 231241.
  • 67 (2010). Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer. Available at: Accessed on 15 January 2013.
  • 68
    Chapman, M. H. and S. P. Pereira (2009) Cholangiocarcinoma: Improving biliary drainage with PDT. Photodiagnosis Photodyn Ther 6, 8283.
  • 69
    Sandanayake, N. S., M. T. Huggett, S. G. Bown, B. W. Pogue, T. Hasan and S. P. Pereira (2010) Photodynamic therapy for locally advanced pancreatic cancer: Early clinical results. In Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIX, Vol. 7551 (Edited by D. Kessel), pp. 75510L8. SPIE, Bellingham, WA, USA, Proceedings of the SPIE (Photonics West), San Francisco, CA, USA.
  • 70
    Bown, S. G., A. Z. Rogowska, D. E. Whitelaw, W. R. Lees, L. B. Lovat, P. Ripley, L. Jones, P. Wyld, A. Gillams and A. W. R. Hatfield (2002) Photodynamic therapy for cancer of the pancreas. Gut 50, 549557.
  • 71
    Ayaru, L., S. G. Bown and S. P. Pereira (2005) Photodynamic therapy for pancreatic and biliary tract carcinoma. Int J Gastrointest Cancer 35, 113.
  • 72
    Kessel, D. and N. L. Oleinick (2009) Initiation of autophagy by photodynamic therapy. Methods Enzymol. 453, 116.
  • 73
    Oleinick, N., R. Morris and I. Belichenko (2002) The role of apoptosis in response to photodynamic therapy: What, where, why, and how. Photochem. Photobiol. Sci. 1, 121.
  • 74
    Buytaert, E., M. Dewaele and P. Agostinis (2007) Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. BBA-Reviews on Cancer 1776, 86107.
  • 75
    Kessel, D., Y. Luo, Y. Deng and C. K. Chang (1997) The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem. Photobiol. 65, 422426.
  • 76
    Kessel, D. and Y. Luo (1998) Mitochondrial photodamage and PDT-induced apoptosis. Journal of Photochemistry and Photobiology B, Biology 42, 8995.
  • 77
    Andrzejak, M., M. Price and D. H. Kessel (2011) Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells. Autophagy 7, 979984.
  • 78
    Casas, A., G. Di Venosa, T. Hasan and B. Al (2011) Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 18, 24862515.
  • 79
    Verma, S., G. M. Watt, Z. Mai and T. Hasan (2007) Strategies for enhanced photodynamic therapy effects. Photochem. Photobiol. 83, 9961005.
  • 80
    Solban, N., I. Rizvi and T. Hasan (2006) Targeted photodynamic therapy. Lasers Surg. Med. 38, 522531.
  • 81
    Gomer, C., A. Ferrario, M. Luna, N. Rucker and S. Wong (2006) Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment. Lasers Surg. Med. 38, 516521.
  • 82
    Ferrario, A. and C. J. Gomer (2010) Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. Methods Mol. Biol. 635, 121132.
  • 83
    Abu-Yousif, A. O., A. C. Moor, X. Zheng, M. D. Savellano, W. Yu, P. K. Selbo and T. Hasan (2012) Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. 321, 120127.
  • 84
    Peng, T. I., C. J. Chang, M. J. Guo, Y. H. Wang, J. S. Yu, H. Y. Wu and M. J. Jou (2005) Mitochondrion-targeted photosensitizer enhances the photodynamic effect-induced mitochondrial dysfunction and apoptosis. Ann. N. Y. Acad. Sci. 1042, 419428.
  • 85
    Granville, D. J., J. G. Levy and D. W. Hunt (1998) Photodynamic treatment with benzoporphyrin derivative monoacid ring A produces protein tyrosine phosphorylation events and DNA fragmentation in murine P815 cells. Photochem. Photobiol. 67, 358362.
  • 86
    Belzacq, A. S., E. Jacotot, H. L. Vieira, D. Mistro, D. J. Granville, Z. Xie, J. C. Reed, G. Kroemer and C. Brenner (2001) Apoptosis induction by the photosensitizer verteporfin: Identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res. 61, 12601264.
  • 87
    Celli, J. P., N. Solban, A. Liang, S. P. Pereira and T. Hasan (2011) Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg. Med. 43, 565574.
  • 88
    Granville, D. J., J. G. Levy and D. W. Hunt (1997) Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ. 4, 623628.
  • 89
    Granville, D. J., C. M. Carthy, D. W. Hunt and B. M. McManus (1998) Apoptosis: Molecular aspects of cell death and disease. Lab. Invest. 78, 893913.
  • 90
    Granville, D. J., C. M. Carthy, H. Jiang, G. C. Shore, B. M. McManus and D. W. Hunt (1998) Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett. 437, 510.
  • 91
    Granville, D. J. and D. W. Hunt (2000) Porphyrin-mediated photosensitization - taking the apoptosis fast lane. Curr. Opin. Drug Discov. Devel. 3, 232243.
  • 92
    Schmidt-Erfurth, U. and T. Hasan (2000) Mechanisms of Action of Photodynamic Therapy with Verteporfin for the Treatment of Age-Related Macular Degeneration. Surv. Ophthalmol. 45, 195214.
  • 93
    Duska, L. R., M. R. Hamblin, J. L. Miller and T. Hasan (1999) Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer ex vivo. J. Natl Cancer Inst. 91, 15571563.
  • 94
    del Carmen, M. G., I. Rizvi, Y. Chang, A. C. Moor, E. Oliva, M. Sherwood, B. Pogue and T. Hasan (2005) Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl Cancer Inst. 97, 15161524.
  • 95
    Wilson, B. C., M. S. Patterson and L. Lilge (1997) Implicit and explicit dosimetry in photodynamic therapy: A New paradigm. Lasers Med. Sci. 12, 182199.
  • 96
    Dysart, J. S., G. Singh and M. S. Patterson (2005) Calculation of singlet oxygen dose from photosensitizer fluorescence and photobleaching during mTHPC photodynamic therapy of MLL cells. Photochem. Photobiol. 81, 196205.
  • 97
    Wilson, B. C. (2007) Photodynamic therapy: Light delivery and dosage for second-generation photosensitizers. In Ciba Foundation Symposium-Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use, Vol. 146. (Edited by G. Bock and S. Harnett). John Wiley & Sons, Ltd., Chichester, UK.
  • 98
    Whitacre, C. M., T. H. Satoh, L. Xue, N. H. Gordon and N. L. Oleinick (2002) Photodynamic therapy of human breast cancer xenografts lacking caspase-3. Cancer Lett. 179, 4349.
  • 99
    Luo, Y., C. K. Chang and D. Kessel (1996) Rapid initiation of apoptosis by photodynamic therapy. Photochem. Photobiol. 63, 528534.
  • 100
    Sheng, C., P. Jack Hoopes, T. Hasan and B. Pogue (2007) Photobleaching-based dosimetry predicts deposited dose in ALA-PpIX PDT of rodent esophagus. Photochem. Photobiol. 83, 738748.
  • 101
    Glidden, M. D., J. P. Celli, I. Massodi, I. Rizvi, B. W. Pogue and T. Hasan (2012) Image-Based Quantification of Benzoporphyrin Derivative Uptake, Localization, and Photobleaching in 3D Tumor Models, for Optimization of PDT Parameters. Theranostics 2, 827839.
  • 102
    Evans, C. L., A. O. Abu-Yousif, Y. J. Park, O. J. Klein, J. P. Celli, I. Rizvi, X. Zheng and T. Hasan (2011) Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT. PLoS ONE 6, e23434.
  • 103
    Celli, J. P., I. Rizvi, A. R. Blanden, A. O. Abu-Yousif, B. Q. Spring and T. Hasan (2011) Biologically-relevant 3D tumor arrays: Imaging-based methods for quantification of reproducible growth and analysis of treatment response. In Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XX, Vol. 7886, (Edited by D. Kessel and T. Hasan), pp. 788608: 18. SPIE, Bellingham, WA, USA, Proceedings of the SPIE (Photonics West), San Francisco, CA, USA.
  • 104
    Celli, J. P., I. Rizvi, C. L. Evans, A. O. Abu-Yousif and T. Hasan (2010) Three-dimensional ovarian cancer models: Imaging and therapeutic combinations. In Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIX, Vol. 7551, (Edited by D. Kessel), pp. 75510I: 110. SPIE, Bellingham, WA, USA, Proceedings of the SPIE (Photonics West), San Francisco, CA, USA.
  • 105
    Celli, J. P., I. Rizvi, A. R. Blanden, C. L. Evans, A. O. Abu-Yousif, B. Q. Spring, A. Muzikansky, B. W. Pogue, D. Finkelstein and T. Hasan (2011) Imaging enabled platforms for development of therapeutics. In Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III, Vol. 7910, (Edited by S. Achilefu and R. Raghavachari), pp. 791002:18. SPIE, Bellingham, WA, USA, Proceedings of the SPIE (Photonics West), San Francisco, CA, USA.
  • 106
    Zhong, W., J. P. Celli, I. Rizvi, Z. Mai, B. Q. Spring, S. H. Yun and T. Hasan (2009) In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br. J. Cancer 101, 20152022.
  • 107
    Ascencio, M., P. Collinet, M. O. Farine and S. Mordon (2008) Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg. Med. 40, 332341.
  • 108
    Ascencio, M., J. P. Estevez, M. Delemer, M. O. Farine, P. Collinet and S. Mordon (2008) Comparison of continuous and fractionated illumination during hexaminolaevulinate-photodynamic therapy. Photodiagnosis Photodyn Ther 5, 210216.
  • 109
    Estevez, J. P., M. Ascencio, P. Colin, M. O. Farine, P. Collinet and S. Mordon (2010) Continuous or fractionated photodynamic therapy? Comparison of three PDT schemes for ovarian peritoneal micrometastasis treatment in a rat model. Photodiagnosis Photodyn Ther 7, 251257.
  • 110
    Guyon, L., M. Ascencio, P. Collinet and S. Mordon (2012) Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer. Photodiagn. Photodyn. Ther. 9, 1647.
  • 111
    Molpus, K. L., M. R. Hamblin, I. Rizvi and T. Hasan (2000) Intraperitoneal Photoimmunotherapy of Ovarian Carcinoma Xenografts in Nude Mice Using Charged Photoimmunoconjugates. Gynecol. Oncol. 76, 397404.
  • 112
    Molpus, K. L., D. Kato, M. R. Hamblin, L. Lilge, M. Bamberg and T. Hasan (1996) Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res. 56, 10751082.
  • 113
    Zuluaga, M. F. and N. Lange (2008) Combination of photodynamic therapy with anti-cancer agents. Curr. Med. Chem. 15, 16551673.
  • 114
    Cengel, K. A., E. Glatstein and S. M. Hahn (2007) Intraperitoneal photodynamic therapy. Cancer Treat. Res. 134, 493514.
  • 115
    Menon, C., S. N. Kutney, S. C. Lehr, S. K. Hendren, T. M. Busch, S. M. Hahn and D. L. Fraker (2001) Vascularity and uptake of photosensitizer in small human tumor nodules: Implications for intraperitoneal photodynamic therapy. Clin. Cancer Res. 7, 39043911.
  • 116
    Dysart, J. S., M. S. Patterson, T. J. Farrell and G. Singh (2002) Relationship between mTHPC fluorescence photobleaching and cell viability during in vitro photodynamic treatment of DP16 cells. Photochem. Photobiol. 75, 289295.
  • 117
    McIlroy, B. W., T. S., Mann, J. S., Dysart, and B. C., Wilson (2002) The effects of oxygenation and photosensitizer substrate binding on the use of fluorescence photobleaching as a dose metric for photodynamic therapy. Vib. Spectrosc. 28, 2535.
  • 118
    Kessel, D. and A. S. Arroyo (2007) Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem. Photobiol. Sci. 6, 12901295.
  • 119
    Xue, L., S. Chiu and N. Oleinick (2001) Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene 20, 34203427.
  • 120
    Winter, W., G. Maxwell, C. Tian, M. Sundborg, G. Rose, P. Rose, S. Rubin, F. Muggia, W. McGuire and G. Gynecologic Oncology (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26, 8392.
  • 121
    Hoskins, W. J., W. P. McGuire, M. F. Brady, H. D. Homesley, W. T. Creasman, M. Berman, H. Ball and J. S. Berek (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170, 974979; discussion 979-80.
  • 122
    Eisenhauer, E., N. Abu-Rustum, Y. Sonoda, C. Aghajanian, R. Barakat and D. Chi (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol. Oncol. 108, 276357.
  • 123
    Chi, D. S., E. L. Eisenhauer, O. Zivanovic, Y. Sonoda, N. R. Abu-Rustum, D. A. Levine, M. W. Guile, R. E. Bristow, C. Aghajanian and R. R. Barakat (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114, 2631.
  • 124
    Lee, S., M. E. Isabelle, K. L. Gabally-Kinney, B. W. Pogue and S. J. Davis (2011) Dual-channel imaging system for singlet oxygen and photosensitizer for PDT. Biomedical Optics Express 2, 12331242.
  • 125
    Aveline, B. M., R. M. Sattler and R. W. Redmond (1998) Environmental effects on cellular photosensitization: Correlation of phototoxicity mechanism with transient absorption spectroscopy measurements. Photochem. Photobiol. 68, 5162.
  • 126
    Baran, T. and T. Foster (2012) Fluence rate-dependent photobleaching of intratumorally administered Pc 4 does not predict tumor growth delay. Photochem. Photobiol. 88, 12731279.
  • 127
    Xue, L. Y., S. M. Chiu and N. L. Oleinick (2001) Photodynamic therapy-induced death of MCF-7 human breast cancer cells: A role for caspase-3 in the late steps of apoptosis but not for the critical lethal event. Exp. Cell Res. 263, 145155.
  • 128
    Porter, A. G. and R. U. Janicke (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6, 99104.
  • 129
    Kessel, D. and J. J. Jr Reiners (2007) Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett. 249, 294299.
  • 130
    Donohue, E., A. Tovey, A. W. Vogl, S. Arns, E. Sternberg, R. N. Young and M. Roberge (2011) Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J. Biol. Chem. 286, 72907300.
  • 131
    Osaki, T., S. Takagi, Y. Hoshino, M. Okumura and T. Fujinaga (2006) Intracellular localization and concentration as well as photodynamic effects of benzoporphyrin derivative monoacid ring A in four types of rodent tumor cells. Cancer Lett. 243, 281292.
  • 132
    Rizvi, I., T. A. Dinh, W. Yu, Y. Chang, M. E. Sherwood and T. Hasan (2012) Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: Perspective and results. Isr. J. Chem. 52, 776787.
  • 133
    Major, A. L., G. S. Rose, L. O. Svaasand, F. Ludicke, A. Campana and M. J. van Gemert (2002) Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5-aminolevulinic acid and violet laser light: A toxicity study. J. Photochem. Photobiol., B 66, 107114.
  • 134
    Haber, D., N. Gray and J. Baselga (2011) The evolving war on cancer. Cell 145, 1924.
  • 135
    Bigelow, C. E., S. Mitra, R. Knuechel and T. H. Foster (2001) ALA- and ALA-hexylester-induced protoporphyrin IX fluorescence and distribution in multicell tumour spheroids. Br. J. Cancer 85, 727734.